Your browser doesn't support javascript.
loading
Impact of Risk Factors on COVID-19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID-19 Global Rheumatology Alliance Registry.
Yazdany, Jinoos; Ware, Anna; Wallace, Zachary S; Bhana, Suleman; Grainger, Rebecca; Hachulla, Eric; Richez, Christophe; Cacoub, Patrice; Hausmann, Jonathan S; Liew, Jean W; Sirotich, Emily; Jacobsohn, Lindsay; Strangfeld, Anja; Mateus, Elsa F; Hyrich, Kimme L; Gossec, Laure; Carmona, Loreto; Lawson-Tovey, Saskia; Kearsley-Fleet, Lianne; Schaefer, Martin; Ribeiro, Sandra Lucia Euzebio; Al-Emadi, Samar; Hasseli, Rebecca; Müller-Ladner, Ulf; Specker, Christof; Schulze-Koops, Hendrik; Bernardes, Miguel; Fraga, Vanessa Machado; Rodrigues, Ana Maria; Sparks, Jeffrey A; Ljung, Lotta; Di Giuseppe, Daniela; Tidblad, Liselotte; Wise, Leanna; Duarte-García, Alí; Ugarte-Gil, Manuel F; Colunga-Pedraza, Iris Jazmín; Martínez-Martínez, Marco Ulises; Alpizar-Rodriguez, Deshire; Xavier, Ricardo Machado; Isnardi, Carolina A; Pera, Mariana; Pons-Estel, Guillermo; Izadi, Zara; Gianfrancesco, Milena A; Carrara, Greta; Scirè, Carlo Alberto; Zanetti, Anna; Machado, Pedro M.
Afiliación
  • Yazdany J; University of California, San Francisco.
  • Ware A; National Center for Collaborative Healthcare Innovation, Palo Alto Department of Veterans Affairs Healthcare System, Palo Alto, California.
  • Wallace ZS; Massachusetts General Hospital and Harvard Medical School, Boston.
  • Bhana S; Pfizer, New York City, New York.
  • Grainger R; University of Otago Wellington and Te Whatu Ora, Health New Zealand Capital, Coast and Hutt Valley, Wellington, New Zealand.
  • Hachulla E; Service de Médecine Interne et Immunologie Clinique, Centre Hospitalier Universitaire (CHU) de Lille, pour la Filière des maladies Auto-Immunes et Autoinflammatoires Rares, Lille, France.
  • Richez C; Service de Rhumatologie, Centre de référence des maladies autoimmunes systémiques rares de l'Est et du Sud-Ouest de France, CHU de Bordeaux, pour la Société Française de Rhumatologie, Bordeaux, France.
  • Cacoub P; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Société Nationale Française de Médecine Interne, Paris, France.
  • Hausmann JS; Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Liew JW; Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts.
  • Sirotich E; Yale School of Medicine, New Haven, Connecticut.
  • Jacobsohn L; University of California, San Francisco.
  • Strangfeld A; German Rheumatism Research Center and Charité University Hospital, Berlin, Germany.
  • Mateus EF; Portuguese League Against Rheumatic Diseases, Lisbon, Portugal, and European Alliance of Associations for Rheumatology, Kilchberg, Switzerland.
  • Hyrich KL; Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester Academic Health Science Centre and NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
  • Gossec L; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique and AP-HP, Pitié-Salpêtrière hospital, Paris, France.
  • Carmona L; Instituto de Salud Musculoesquelética, Madrid, Spain.
  • Lawson-Tovey S; Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
  • Kearsley-Fleet L; Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
  • Schaefer M; German Rheumatism Research Center, Berlin, Germany.
  • Ribeiro SLE; Federal University of Amazonas, Manaus, Brazil.
  • Al-Emadi S; Hamad General Hospital, Doha, Qatar.
  • Hasseli R; University Hospital Munster, Munster, Germany, and Justus Liebig University Giessen, Kerckhoff, Germany.
  • Müller-Ladner U; Justus Liebig University Giessen, Kerckhoff, Germany.
  • Specker C; Kliniken Essen-Mitte, Essen, Germany.
  • Schulze-Koops H; University of Munich, Munich, Germany.
  • Bernardes M; University of Porto and Centro Hospitalar e Universitário de São João, Porto, Portugal.
  • Fraga VM; Hospital Garcia de Orta, Almada, Portugal.
  • Rodrigues AM; Sociedade Portuguesa de Reumatologia and Comprehensive Health Research Centre, Nova Medical School, Universidade Nova de Lisboa, Lisbon, Portugal.
  • Sparks JA; Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Ljung L; Karolinska Institutet and Academic Specialist Centre, Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden.
  • Di Giuseppe D; Karolinska Institutet, Stockholm, Sweden.
  • Tidblad L; Karolinska Institutet, Stockholm, Sweden.
  • Wise L; Keck School of Medicine, University of Southern California, Los Angeles.
  • Duarte-García A; Mayo Clinic, Rochester, Minnesota.
  • Ugarte-Gil MF; Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémica, Universidad Científica del Sur and Hospital Nacional Guillermo Almenara Irigoyen - EsSalud, Lima, Peru.
  • Colunga-Pedraza IJ; Hospital Universitario José Eleuterio González, Monterrey, Mexico.
  • Martínez-Martínez MU; Hospital General de Subzona No. 9, Instituto Mexicano del Seguro Social, San Luis, Potosí, Mexico.
  • Alpizar-Rodriguez D; Colegio Mexicano de Reumatología, Mexico City, Mexico.
  • Xavier RM; Universidade Federal do Rio Grande do Sul, Serviço de Reumatologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
  • Isnardi CA; Argentine Society of Rheumatology, Buenos Aires, Argentina.
  • Pera M; Hospital Angel C. Padilla, San Miguel de Tucuman, Tucuman, Argentina.
  • Pons-Estel G; Universidad Nacional de Rosario, Rosario, Argentina, and College of Physicians of the Province of Santa Fe 2nd, Santa Fe, Argentina.
  • Izadi Z; University of California, San Francisco.
  • Gianfrancesco MA; University of California, San Francisco.
  • Carrara G; Italian Society for Rheumatology, Milan, Italy.
  • Scirè CA; Italian Society for Rheumatology and School of Medicine, University of Milano-Bicocca, Milan, Italy.
  • Zanetti A; Italian Society for Rheumatology, Milan, Italy.
  • Machado PM; University College London, NIHR University College London Hospitals Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, and Northwick Park Hospital, London North West University Healthcare NHS Trust, London, UK.
Arthritis Care Res (Hoboken) ; 76(2): 274-287, 2024 Feb.
Article en En | MEDLINE | ID: mdl-37643903
ABSTRACT

OBJECTIVE:

Approximately one third of individuals worldwide have not received a COVID-19 vaccine. Although studies have investigated risk factors linked to severe COVID-19 among unvaccinated people with rheumatic diseases (RDs), we know less about whether these factors changed as the pandemic progressed. We aimed to identify risk factors associated with severe COVID-19 in unvaccinated individuals in different pandemic epochs corresponding to major variants of concern.

METHODS:

Patients with RDs and COVID-19 were entered into the COVID-19 Global Rheumatology Alliance Registry between March 2020 and June 2022. An ordinal logistic regression model (not hospitalized, hospitalized, and death) was used with date of COVID-19 diagnosis, age, sex, race and/or ethnicity, comorbidities, RD activity, medications, and the human development index (HDI) as covariates. The main analysis included all unvaccinated patients across COVID-19 pandemic epochs; subanalyses stratified patients according to RD types.

RESULTS:

Among 19,256 unvaccinated people with RDs and COVID-19, those who were older, male, had more comorbidities, used glucocorticoids, had higher disease activity, or lived in lower HDI regions had worse outcomes across epochs. For those with rheumatoid arthritis, sulfasalazine and B-cell-depleting therapy were associated with worse outcomes, and tumor necrosis factor inhibitors were associated with improved outcomes. In those with connective tissue disease or vasculitis, B-cell-depleting therapy was associated with worse outcomes.

CONCLUSION:

Risk factors for severe COVID-19 outcomes were similar throughout pandemic epochs in unvaccinated people with RDs. Ongoing efforts, including vaccination, are needed to reduce COVID-19 severity in this population, particularly in those with medical and social vulnerabilities identified in this study.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Reumatología / Enfermedades Reumáticas / COVID-19 Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Arthritis Care Res (Hoboken) Asunto de la revista: REUMATOLOGIA Año: 2024 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Reumatología / Enfermedades Reumáticas / COVID-19 Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Arthritis Care Res (Hoboken) Asunto de la revista: REUMATOLOGIA Año: 2024 Tipo del documento: Article